Meeting
2022 ASCO Quality Care Symposium
Impact of acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy on health-related quality of life (HRQOL) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
Authors
Donald Patrick
School of Public Health, University of Washington, Seattle, WA
Donald Patrick, Shauna McManus, Lauren Podger, Ashley Saunders, Julia Braverman, Fei Fei Liu, Scott J. Keating
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Symptom Prevention, Assessment, and Management
Clinical Trial Registration Number
NCT02631044
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 294)
DOI
10.1200/JCO.2022.40.28_suppl.294
Abstract #
294
Poster Bd #
G33
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2021 ASCO Annual Meeting
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
First Author: Larry D. Anderson, Jr
Poster
2020 ASCO Virtual Scientific Program
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
First Author: Alison R. Sehgal
Poster
2020 ASCO Virtual Scientific Program
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
First Author: Sairah Ahmed